Compare Mesoblast Limited (MESO) vs Rent the Runway Inc (RENT) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

RENT trades at $3.64, down 1.09% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 29.2% year-over-year to $89.9 million, beating expectations, but net losses persist. Analyst sentiment is mixed with 42% buy ratings, while cash flow remains negative and debt levels are elevated.

The outlook hinges on execution under new leadership to achieve profitability. Investment opportunity lies in low valuation multiples if subscriber growth accelerates, but risks include high leverage and sustained cash burn. Wall Street consensus leans cautious despite recent earnings beats.